Galderma, held an event on March 9 to introduce its new liquid
BoNT-A neuromodulator, Alluzience.
Unlike all other BoNT-A products currently approved in Europe that come in powder form and require reconstitution with sodium chloride before use, Alluzience is a ready-to-use formulation. This avoids any calculations and allows for more precision, meaning that the product has the potential to improve safety and dosing accuracy compared with powder-form BoNT-A preparations, says Galderma.
Gerry Muhle, the head of the company's global business unit, gave a brief welcome speech and provided an overview of the company's history and future plans.
Throughout the evening, key opinion leaders from Galderma discussed the benefits of Alluzience.
Alice Henshaw, a nurse prescriber, discussed the precision of the product, while Kuldeep Minocha, an aesthetic practitioner, focused on its performance and safety.
Priya Chadha, a plastic surgery registrar, emphasized the product's improvement in patient psychological well-being, as well as its easy-to-use liquid formulation and lack of animal or human-derived excipients.
Plus, Yusra Al-Mukhtar, an aesthetic practitioner, highlighted the importance of patients' psychological well-being and shared a video of patients discussing how aesthetic treatments helped them regain confidence.
The talks included evidence from clinical studies that showed high patient satisfaction, safety, and tolerability, as well as information on adverse events and contraindications for use.
“We are very proud to have launched our new product in London – it was our pleasure to see the great interest in our innovation. Our launch meeting was attended by more than 250 healthcare practitioners in-person, as well as watched online. Galderma will continue its commitment to bring new scientific solutions to our customers and drive innovation in the future.”
- Rene Wipperich, general manager at Galderma